Opinion

Video

Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • Please discuss the data for 2L treatment with CAR T-cell therapy for patients who are transplant-ineligible.
      • Do the defining characteristics of transplant-ineligible used in the following studies reflect which patients are considered transplant-ineligible in the real world?
      • ALYCANTE- Phase 2 trial.
      • PILOT – Phase 2 trial.
      • What are some key takeaways from the results of these two studies?

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data

    Related Content